Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug: HY001N Cell Injection The dose was incremented according to the "3+3" principle, and the three dose levels A, B and C were given in sequence at one time, which were respectively: A-1 dose group: 0.25×10\^5 CAR-T live cells /kg body weight Group A (initial dose) : 0.5×10\^5 CAR-T live cells /kg body weight Group B: 1.0×10\^5 CAR-T live cells /kg body weight Group C: 1.5×10\^5 CAR-T live…”In the company’s words, NCT07748533 on ClinicalTrials.gov
- Tested for
- Autoimmune Hemolytic Anemia (AIHA)
- Main trialPhase 1
- “The goal of this clinical trial is to learn if HY001N cell injection safety and tolerability in adult patients with autoimmune hemolytic anemia after failure of 3 or more lines of therapy. It will also learn about the efficacy of HY001N cell injection to treat adult patients with autoimmune hemolytic anemia. The main questions it aims to answer are: Proportion of participants attaining a CR (defined as normalization of hemoglobin not attributed to transfusion effect and the normalization of hemolytic markers) or CRi (defined as normalization of hemoglobin not attributed to transfusion effect…”In the company’s words, NCT07748533 on ClinicalTrials.gov
Other drugs for Autoimmune Hemolytic Anemia (AIHA)
- RilzabrutinibSanofi · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 1/2
- BMS-986353Bristol Myers Squibb · Phase 2
- OM336Lakefront Biotherapeutics West LLC · Phase 1
- YTS109China Immunotech (Beijing) Biotechnology Co., Ltd. · Phase 1
- Arnovie101Circunited BioPharma · Early Phase 1
Coming up1
- 1 Sep 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Sep 2028 | HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026